Ascendis Pharma A/S (ASND)
Health Care
Ascendis Pharma A/S (ASND) is listed on Nasdaq, where its shares have traded since April 20, 2026. SentiSense covers Ascendis Pharma A/S in the Health Care sector. Jan Møller Mikkelsen is its chief executive officer. The company reports 1,189 employees, and its corporate website is www.ascendispharma.com.
About Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 302 institutions reported holding ASND, with 66.9 million shares worth $17.8 billion in aggregate. The largest reported holders were RA Capital Management, T. Rowe Price and Avoro Capital Advisors. Of the 5 largest reported holders, 1 opened a new position in ASND, 2 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
More on ASND
- ASND sentiment: whether news and social coverage of Ascendis Pharma A/S leans bullish or bearish, and the stories driving it.
- ASND ownership: all 302 reporting institutions, plus insider and congressional trades.
- ASND financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Ascendis Pharma A/S: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Ascendis Pharma A/S do?
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients.
What sector is ASND in?
SentiSense classifies Ascendis Pharma A/S in the Health Care sector.
Where does ASND stock trade?
Ascendis Pharma A/S (ASND) is listed on Nasdaq, where its shares have traded since April 20, 2026.
Who is the CEO of Ascendis Pharma A/S?
Jan Møller Mikkelsen is the chief executive officer of Ascendis Pharma A/S.